Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Clin Cancer Res
; 23(14): 3794-3801, 2017 Jul 15.
Article
in En
| MEDLINE
| ID: mdl-28159814
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Biomarkers, Tumor
/
Bevacizumab
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2017
Document type:
Article
Affiliation country:
Country of publication: